AZN vs. HLN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AZN and HLN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
AZN’s market capitalization of 430.65 billion USD is substantially larger than HLN’s 46.09 billion USD, indicating a significant difference in their market valuations.
With betas of 0.17 for AZN and 0.24 for HLN, both stocks show similar sensitivity to overall market movements.
AZN and HLN are both American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies without directly engaging with overseas stock exchanges.
| Symbol | AZN | HLN |
|---|---|---|
| Company Name | AstraZeneca PLC | Haleon plc |
| Country | GB | GB |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - Specialty & Generic |
| CEO | Pascal Claude Roland Soriot | Brian James McNamara |
| Price | 69.45 USD | 10.25 USD |
| Market Cap | 430.65 billion USD | 46.09 billion USD |
| Beta | 0.17 | 0.24 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 12, 1993 | July 25, 2022 |
| ADR | Yes | Yes |
Historical Performance
This chart compares the performance of AZN and HLN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
AZN
19.18%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
AZN’s Return on Equity of 19.18% is on par with the norm for the Drug Manufacturers - General industry, indicating its profitability relative to shareholder equity is typical for the sector.
HLN
8.73%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 51.32%
- Q3
- 9.89%
- Median
- -3.37%
- Q1
- -20.99%
- Min
- -36.07%
HLN’s Return on Equity of 8.73% is on par with the norm for the Drug Manufacturers - Specialty & Generic industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
AZN
10.93%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
AZN’s Return on Invested Capital of 10.93% is in line with the norm for the Drug Manufacturers - General industry, reflecting a standard level of efficiency in generating profits from its capital base.
HLN
5.68%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 22.54%
- Q3
- 8.45%
- Median
- 1.42%
- Q1
- -9.01%
- Min
- -28.41%
HLN’s Return on Invested Capital of 5.68% is in line with the norm for the Drug Manufacturers - Specialty & Generic industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
AZN
14.14%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
AZN’s Net Profit Margin of 14.14% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
HLN
12.84%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 40.33%
- Q3
- 11.92%
- Median
- -0.45%
- Q1
- -13.07%
- Min
- -34.27%
A Net Profit Margin of 12.84% places HLN in the upper quartile for the Drug Manufacturers - Specialty & Generic industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
AZN
19.21%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
AZN’s Operating Profit Margin of 19.21% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.
HLN
19.64%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 46.91%
- Q3
- 19.02%
- Median
- 6.23%
- Q1
- -11.23%
- Min
- -51.89%
An Operating Profit Margin of 19.64% places HLN in the upper quartile for the Drug Manufacturers - Specialty & Generic industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | AZN | HLN |
|---|---|---|
| Return on Equity (TTM) | 19.18% | 8.73% |
| Return on Assets (TTM) | 7.31% | 4.20% |
| Return on Invested Capital (TTM) | 10.93% | 5.68% |
| Net Profit Margin (TTM) | 14.14% | 12.84% |
| Operating Profit Margin (TTM) | 19.21% | 19.64% |
| Gross Profit Margin (TTM) | 81.41% | 61.52% |
Financial Strength
Current Ratio
AZN
0.90
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
AZN’s Current Ratio of 0.90 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
HLN
0.98
Drug Manufacturers - Specialty & Generic Industry
- Max
- 5.74
- Q3
- 3.37
- Median
- 2.64
- Q1
- 1.73
- Min
- 0.88
HLN’s Current Ratio of 0.98 falls into the lower quartile for the Drug Manufacturers - Specialty & Generic industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
AZN
0.77
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
AZN’s Debt-to-Equity Ratio of 0.77 is typical for the Drug Manufacturers - General industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
HLN
0.62
Drug Manufacturers - Specialty & Generic Industry
- Max
- 1.45
- Q3
- 1.06
- Median
- 0.62
- Q1
- 0.13
- Min
- 0.00
HLN’s Debt-to-Equity Ratio of 0.62 is typical for the Drug Manufacturers - Specialty & Generic industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
AZN
7.95
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
AZN’s Interest Coverage Ratio of 7.95 is positioned comfortably within the norm for the Drug Manufacturers - General industry, indicating a standard and healthy capacity to cover its interest payments.
HLN
5.60
Drug Manufacturers - Specialty & Generic Industry
- Max
- 10.17
- Q3
- 3.39
- Median
- 0.85
- Q1
- -2.63
- Min
- -5.84
HLN’s Interest Coverage Ratio of 5.60 is in the upper quartile for the Drug Manufacturers - Specialty & Generic industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | AZN | HLN |
|---|---|---|
| Current Ratio (TTM) | 0.90 | 0.98 |
| Quick Ratio (TTM) | 0.70 | 0.78 |
| Debt-to-Equity Ratio (TTM) | 0.77 | 0.62 |
| Debt-to-Asset Ratio (TTM) | 0.30 | 0.29 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.49 | 3.41 |
| Interest Coverage Ratio (TTM) | 7.95 | 5.60 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for AZN and HLN. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
AZN
1.87%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
AZN’s Dividend Yield of 1.87% is in the lower quartile for the Drug Manufacturers - General industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
HLN
0.90%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 9.29%
- Q3
- 0.31%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.90%, HLN offers a more attractive income stream than most of its peers in the Drug Manufacturers - Specialty & Generic industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
AZN
63.60%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
AZN’s Dividend Payout Ratio of 63.60% is within the typical range for the Drug Manufacturers - General industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
HLN
0.00%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 125.42%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HLN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | AZN | HLN |
|---|---|---|
| Dividend Yield (TTM) | 1.87% | 0.90% |
| Dividend Payout Ratio (TTM) | 63.60% | 0.00% |
Valuation
Price-to-Earnings Ratio
AZN
28.12
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
At 28.12, AZN’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Drug Manufacturers - General industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
HLN
23.92
Drug Manufacturers - Specialty & Generic Industry
- Max
- 40.89
- Q3
- 28.12
- Median
- 23.94
- Q1
- 18.79
- Min
- 7.76
HLN’s P/E Ratio of 23.92 is within the middle range for the Drug Manufacturers - Specialty & Generic industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
AZN
2.56
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
AZN’s Forward PEG Ratio of 2.56 is within the middle range of its peers in the Drug Manufacturers - General industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
HLN
-0.24
Drug Manufacturers - Specialty & Generic Industry
- Max
- 4.19
- Q3
- 2.94
- Median
- 1.47
- Q1
- 0.35
- Min
- 0.00
HLN has a negative Forward PEG Ratio of -0.24. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
Price-to-Sales Ratio
AZN
3.98
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
AZN’s P/S Ratio of 3.98 aligns with the market consensus for the Drug Manufacturers - General industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
HLN
3.03
Drug Manufacturers - Specialty & Generic Industry
- Max
- 7.49
- Q3
- 4.45
- Median
- 2.12
- Q1
- 1.21
- Min
- 0.25
HLN’s P/S Ratio of 3.03 aligns with the market consensus for the Drug Manufacturers - Specialty & Generic industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
AZN
5.33
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
HLN
2.13
Drug Manufacturers - Specialty & Generic Industry
- Max
- 4.93
- Q3
- 3.95
- Median
- 2.14
- Q1
- 1.30
- Min
- 0.13
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - Specialty & Generic industry.
Valuation at a Glance
| Symbol | AZN | HLN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 28.12 | 23.92 |
| Forward PEG Ratio (TTM) | 2.56 | -0.24 |
| Price-to-Sales Ratio (P/S, TTM) | 3.98 | 3.03 |
| Price-to-Book Ratio (P/B, TTM) | 5.33 | 2.13 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.59 | -- |
| EV-to-EBITDA (TTM) | 13.82 | 18.06 |
| EV-to-Sales (TTM) | 4.46 | 3.73 |